Published in Gastroenterology on January 18, 2010
Living in the liver: hepatic infections. Nat Rev Immunol (2012) 2.03
In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology (2011) 1.69
Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol (2011) 1.55
Natural killer cells in liver disease. Hepatology (2013) 1.31
KIR/HLA interactions and pathogen immunity. J Biomed Biotechnol (2011) 1.26
STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. J Hepatol (2012) 1.15
Involvement of activating NK cell receptors and their modulation in pathogen immunity. J Biomed Biotechnol (2011) 1.10
Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience. Curr Opin Virol (2011) 1.09
Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells. J Virol (2011) 1.03
A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology (2011) 1.03
Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta (2012) 1.00
Liver immunology. Compr Physiol (2013) 0.99
Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection. Hepatology (2013) 0.96
Activation of natural killer cells during microbial infections. Front Immunol (2012) 0.96
Natural Killer Cells in Viral Hepatitis. Cell Mol Gastroenterol Hepatol (2015) 0.96
Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev (2013) 0.95
IFN-γ production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells. J Hepatol (2013) 0.94
Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS One (2014) 0.92
HIV and co-infections. Immunol Rev (2013) 0.92
The evolution of natural killer cell receptors. Immunogenetics (2015) 0.92
Know Thyself: NK-Cell Inhibitory Receptors Prompt Self-Tolerance, Education, and Viral Control. Front Immunol (2014) 0.91
Baseline and Dynamic Expression of Activating NK Cell Receptors in the Control of Chronic Viral Infections: The Paradigm of HIV-1 and HCV. Front Immunol (2014) 0.89
NK cell activation in human hantavirus infection explained by virus-induced IL-15/IL15Rα expression. PLoS Pathog (2014) 0.87
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Innate immune cell networking in hepatitis C virus infection. J Leukoc Biol (2014) 0.86
NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis (2011) 0.86
Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol (2016) 0.86
Immunity and hepatitis C: a review. Curr HIV/AIDS Rep (2013) 0.85
Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection. J Gastroenterol (2011) 0.85
Killer-cell immunoglobulin-like receptors (KIR) in severe A (H1N1) 2009 influenza infections. Immunogenetics (2012) 0.85
Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection. J Interferon Cytokine Res (2013) 0.82
The natural killer cell response to HCV infection. Immune Netw (2013) 0.82
Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-γ Production by Altering Cellular Metabolism via Arginase-1. J Immunol (2016) 0.80
Activation of natural killer cells by hepatitis C virus particles in vitro. Clin Exp Immunol (2011) 0.79
NK cell function and receptor diversity in the context of HCV infection. Front Microbiol (2015) 0.79
Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. Clin Exp Immunol (2015) 0.78
Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients. Mediators Inflamm (2012) 0.78
Human NK Cell Diversity in Viral Infection: Ramifications of Ramification. Front Immunol (2016) 0.78
Organ system view of the hepatic innate immunity in HCV infection. J Med Virol (2016) 0.78
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. Genes Immun (2015) 0.77
Extracellular HCV-core protein induces an immature regulatory phenotype in NK cells: implications for outcome of acute infection. PLoS One (2014) 0.77
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol (2013) 0.76
Natural killer cells in hepatitis C: Current progress. World J Gastroenterol (2016) 0.76
Natural Killer Cell Diversity in Viral Infection: Why and How Much? Pathog Immun (2016) 0.76
The natural killer cell response to West Nile virus in young and old individuals with or without a prior history of infection. PLoS One (2017) 0.75
Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus. PLoS One (2017) 0.75
IFN-λ3 polymorphism indirectly influences NK cell phenotype and function during acute HCV infection. Immun Inflamm Dis (2016) 0.75
Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection. J Virol (2016) 0.75
Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol (2015) 0.75
Hepatitis C Virus Stimulates Murine CD8α-Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. PLoS Pathog (2016) 0.75
Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism. Virusdisease (2016) 0.75
NK cell recognition. Annu Rev Immunol (2005) 14.40
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol (2008) 7.88
Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 6.73
Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50
Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med (2002) 4.67
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32
KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol (2001) 4.24
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med (2002) 2.68
Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology (2009) 2.66
Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology (2006) 2.65
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 2.64
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol (1999) 2.39
Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut (2005) 1.99
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol (2007) 1.86
NK cells at the interface between innate and adaptive immunity. Cell Death Differ (2007) 1.83
Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol (2006) 1.82
Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol (2005) 1.62
Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol (2004) 1.59
Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest (2008) 1.52
Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut (2008) 1.47
Natural killer cell activation in mice and men: different triggers for similar weapons? Nat Immunol (2002) 1.44
Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol (2009) 1.43
Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol (2005) 1.41
Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology (2009) 1.40
Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Mol Immunol (2008) 1.36
Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol (2009) 1.07
Normalization of depressed natural killer activity after interferon-alpha therapy is associated with a low frequency of relapse in patients with chronic hepatitis C. Int J Tissue React (1993) 1.04
The dialogue between human natural killer cells and dendritic cells. Curr Opin Immunol (2005) 1.03
CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. Clin Exp Immunol (2004) 0.91
Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C. J Leukoc Biol (2006) 0.81
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol (2008) 6.90
PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol (2006) 5.46
Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol (2007) 4.40
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology (2004) 2.87
Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology (2007) 2.78
HIV-1 adaptation to NK-cell-mediated immune pressure. Nature (2011) 2.59
T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol (2005) 2.58
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol (2003) 2.50
Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol (2002) 2.26
Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J Hepatol (2013) 2.04
Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology (2006) 1.96
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut (2011) 1.78
Kinetics of the immune response during HBV and HCV infection. Hepatology (2003) 1.77
Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A (2010) 1.72
Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology (2010) 1.72
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One (2011) 1.69
Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med (2005) 1.68
Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology (2009) 1.65
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology (2010) 1.61
Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology (2010) 1.59
Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J Hepatol (2004) 1.56
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology (2012) 1.49
Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res (2006) 1.44
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology (2008) 1.42
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol (2005) 1.30
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology (2006) 1.28
KIR/HLA interactions and pathogen immunity. J Biomed Biotechnol (2011) 1.26
Natural killer cells: integrating diversity with function. Immunology (2009) 1.25
Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol (2008) 1.23
Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol (2008) 1.21
Conservation and variation in human and common chimpanzee CD94 and NKG2 genes. J Immunol (2002) 1.21
Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol (2002) 1.20
Hanging in the balance. KIR and their role in disease. Mol Interv (2005) 1.17
Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol (2010) 1.15
Natural killer cells and hepatitis C: action and reaction. Gut (2010) 1.15
The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther (2010) 1.14
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer (2014) 1.13
Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience. Curr Opin Virol (2011) 1.09
Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Hepatology (2002) 1.07
The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med (2010) 1.06
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology (2007) 1.06
Transvaginal endoscopic cholecystectomy in human beings: preliminary results. J Laparoendosc Adv Surg Tech A (2008) 1.05
Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology (2005) 1.05
Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans. PLoS Pathog (2010) 1.03
A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology (2011) 1.03
KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection. PLoS Pathog (2011) 1.02
Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother (2008) 1.01
Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. Hepatology (2002) 0.98
Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut (2012) 0.98
RepeatsDB: a database of tandem repeat protein structures. Nucleic Acids Res (2013) 0.97
Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology (2012) 0.96
The impairment of CD8 responses limits the selection of escape mutations in acute hepatitis C virus infection. J Immunol (2005) 0.96